A 65-year-old male veteran with no prior psychiatric history and a past medical history of seizure disorder developed severe, treatment-resistant depression after witnessing his mother’s ...
This project explores the integration of mindfulness meditation with esketamine in the treatment of major depressive disorder. Conducted as a quasi-experimental pilot, the study involved ...
Up to 50% of adults with schizophrenia switch antipsychotic medication within 2 years of treatment initiation. We conducted a real-world analysis of strategies used by healthcare provider...
This real-world claims analysis compared combined olanzapine/samidorphan (OLZ/SAM) versus olanzapine in patients with bipolar I disorder. OLZ/SAM was associated with significantly better ...
Short description: Prior pharmacokinetic studies of X/T in healthy volunteers showed dosing with food reduced trospium bioavailability, potentially impacting tolerability. This open-label...
TV-44749 is a once-monthly subcutaneous long-acting injectable olanzapine, designed to provide sustained efficacy without the risk of post-injection delirium/sedation syndrome (PDSS). Her...
CRESCENDO was a survey of the patient experience in adults with narcolepsy type 1. This subgroup analysis examined residual symptoms among respondents who reported satisfaction with curre...
Jazz DUET (NCT05875974) was a patient-centric, prospective, single-arm, open-label study evaluating effectiveness of low-sodium oxybate (LXB) in IH or narcolepsy. In participants with IH,...
Severe hypothyroidism can present with predominant psychiatric and cognitive symptoms, making diagnosis challenging when classic somatic signs are absent. This poster explores the neurops...
Short Description: This Phase 3, double-blind, randomized study (NCT04959032) investigated the efficacy and safety of lumateperone 42 mg for relapse prevention in adult patients with schi...
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
